Randomization & Trial Supply Management (RTSM)

Empowering Clinical Trials: Streamlining Randomization and Supply Management with RTSM Solutions

What is RTSM?

RTSM (Randomization and Trial Supply Management) systems enable study teams to manage patient randomization and supply investigational drugs, placebos, and/or medical devices to sites throughout the study lifecycle. RTSM systems are alternatively called Interactive Response Technology (IRT), which encompasses IWRS, IVRS, and IxRS (Interactive Web, Voice, and Voice/Web Response Systems).

These technologies supported site staff in obtaining study kit information, especially when computers were not widely available in surgical rooms. Today, web access is more prevalent in hospital settings, so staff may leverage centralized RTSM systems to manage patients dosages. IxRS is still commonly used throughout the world.

Woman wearing lab coat and gloves looking into microscope
Hands typing on laptop displaying diagram of DNA double helix

Patients must be assigned into different treatment arms via randomization to balance known and unknown subject attributes and demonstrate validity of statistical comparisons. This process is complicated due to Sponsor/CRO requirements such as double blindness (neither patient nor study team knowing which treatment was obtained), complex stratifications, and ability to recruit patients globally while maintaining oversight from a centralized location. With high volumes of subjects, it’s easy to incorrectly assign a randomization number or dispense the wrong treatment kit.

Unlike other clinical systems, such as CTMS and eTMF, that may be managed fully in-house, Sponsors typically rely on IRT vendors to set up studies and provide professional/validation services due to the build complexity.

Key Benefits of RTSM/IRT Systems

Commissioning, qualification, validation icon

Efficient Randomization and Blind Protection

RTSM automates patient enrollment and randomization, reducing human error and bias. It ensures allocation concealment and maintains study blinding. RTSM...

Read More

Efficient Randomization and Blind Protection

RTSM automates patient enrollment and randomization, reducing human error and bias. It ensures allocation concealment and maintains study blinding. RTSM systems have security settings that ensure only a restricted set of users may unblind the patient in case of emergency.

Read Less
Calendar icon

Reduce Trial Delays

Advancements in IRT facilitate adaptive trial design, study start-up, and protocol amendment more quickly than ever. By leveraging pre-built libraries, Sponsors/CROs may shift...

Read More

Reduce Trial Delays

Advancements in IRT facilitate adaptive trial design, study start-up, and protocol amendment more quickly than ever. By leveraging pre-built libraries, Sponsors/CROs may shift away from study-by-study deployment to support mid-study changes. Automation supports cohort management, patient enrollment, drug dispensation, inventory management, and screen failures. With audit trails and user-based access, regulatory compliance is enforced throughout all these processes.

Read Less
Regulatory CMC icon

Optimize Trial Supply Management

Late or damaged shipments can result in patients receiving an unusable product or being disqualified for missing a dose. RTSM technology can not only track unused or...

Read More

Optimize Trial Supply Management

Late or damaged shipments can result in patients receiving an unusable product or being disqualified for missing a dose. RTSM technology can not only track unused or returned drugs during the trial, but it can also be configured to support multiple direct-to-patient shipping scenarios. Resupply can be set predictively or automatically based on actual site enrollment numbers to ensure sites are adequately stocked. Furthermore, you can set system alerts for low depot supply, delayed shipments, and upcoming expiry dates.

Read Less

Important Considerations for RTSM Implementation

Implementation and vendor selection comprise an arduous process, and Sponsors are often unsure what to ask. As novel trial and master protocol designs evolve, the complexity of these decisions will likely grow. For a successful RTSM implementation, consider the following:

  • Study Build Timelines: Sometimes, the core RTSM application will not meet every need of your trial design. Allocate time for the vendor to develop custom programming to incorporate your requirements into the system.
  • Vendor Expertise: Choose an experienced vendor who acts as a partner, understands your study’s unique requirements, and provides expert advice. ProPharma specializes in vendor assessment, guiding your organization through RFX and system demos to select a fit-for-purpose system.
  • Functionality and Flexibility: At a minimum, ensure that the system can accommodate complex protocols, adaptive studies, multiple-subject cohorts, and advanced randomization methods as needed for your drug/therapeutic area.
  • Interoperability: Many clinical trial processes are housed in disparate systems; for example, Sponsors may wish to have the randomization form in EDC and site activation conducted in CTMS. RTSM systems should offer published APIs to integrate with EDC and CTMS.
Two data professionals reviewing data on computer monitor
Two engineers reviewing a small computer device in front of two computer monitors

Popular Vendors in the RTSM/IRT Space

  • EndPoint PULSE: with pre-validated, configurable study components, PULSE streamlines system modifications and simplifies site, user, and supply management.
  • Medidata RTSM: fully pre-validated solution that enables mid-study changes and integrates seamlessly with Rave EDC.
  • Suvoda IRT: offers rich functionality in cohort/stage/phase management, adaptive replacement and randomization, and drug accountability and reconciliation.
  • Veeva RTSM (previously Veracity Logic): modular, quick to configure, and offers features like screening, rescreening, adaptive randomizations, and cohort management.
  • YPrime IRT: provides flexible supply management, Sponsor-controlled cohort management, and easy adjustment of dispensing levels.

ProPharma's RTSM Services & Approach

ProPharma’s R&D Technology team understands the criticality of selecting the right RTSM and excels in aligning your company’s needs with regulations and GxP system best practices. Our comprehensive approach and expert knowledge ensure that your organization is set up for long-term success.

Service Category

How We Can Help

Strategy & Business Process Optimization

  • RTSM System Selection
  • Roadmap Development

Clinical Research Solutions

  • Staff Augmentation

Implementation Support

  • Project Management
  • Configuration & API Integrations (Reporting, EDCs, Datalake)
  • Controlled Document Creation (SOPs, Work Instructions, and Job Aids)
  • User Administration & Training
  • Change Management

Validation

  • Validation Coordination
  • User Acceptance Testing

Managed Services

  • System Administration
  • Release Management
  • System Optimization

RTSM Consulting Expertise

If you want to implement or optimize your RTSM, ProPharma's R&D Technology team comprises experienced consultants who can advise your digital transformation. Contact us to speak with one of our RTSM / IRT experts today.

News & Insights

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

The Strategic Importance of a Consumer Health Service Line

April 27, 2026

The Strategic Importance of a Consumer Health Service Line

Explore how Consumer Health brands can enhance consumer engagement through proactive service strategies, ensuring safety, compliance, and brand loyalty in a complex market.

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

April 22, 2026

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI ...

The FDA's warning letter to Purolea Cosmetics Lab highlights the need for rigorous AI governance in pharmaceutical manufacturing. Compliance is crucial for product quality and safety.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity Expectations

April 30, 2026

Cyberattacks in MedTech: Lessons from Stryker, Intuitive, & FDA's Cybersecurity ...

Recent cyberattacks on MedTech leaders highlight growing regulatory and patient safety risks. Explore key lessons and how FDA cybersecurity guidance is shaping compliance and resilience.

The Strategic Importance of a Consumer Health Service Line

April 27, 2026

The Strategic Importance of a Consumer Health Service Line

Explore how Consumer Health brands can enhance consumer engagement through proactive service strategies, ensuring safety, compliance, and brand loyalty in a complex market.

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

April 22, 2026

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI ...

The FDA's warning letter to Purolea Cosmetics Lab highlights the need for rigorous AI governance in pharmaceutical manufacturing. Compliance is crucial for product quality and safety.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Whitepapers IND Readiness Checklist: Assess Your FDA Submission Risk

May 4, 2026

IND Readiness Diagnostic: 12 Questions Sponsors Should Answer Before Submitting

A Practical Framework to Assess IND Readiness Before Filing Identify gaps early. Reduce FDA risk. Strengthen your submission strategy. Preparing for an Investigational New Drug (IND) submission...

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow